Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

被引：158

作者：

Hua, Hui ^{[1
]}

Kong, Qingbin ^{[2
]}

Yin, Jie ^{[2
]}

Zhang, Jin ^{[2
]}

Jiang, Yangfu ^{[2
]}

机构：

[1] Sichuan Univ, State Key Lab Biotherapy, Lab Stem Cell Biol, Natl Clin Res Ctr Geriatr,West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Ctr Canc, State Key Lab Biotherapy,Lab Oncogene, Chengdu 610041, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2020年 / 13卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Insulin-like growth factor; Cancer; Receptor tyrosine kinase; Tumorigenesis; Drug resistance; FACTOR-I RECEPTOR; TARGETING IGF-IR; EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE-ACTIVITY; PATHWAY RATIONAL BASIS; RANDOMIZED PHASE-II; BREAST-CANCER; LINSITINIB OSI-906; MONOCLONAL-ANTIBODY; TUMOR-CELLS;

D O I：

10.1186/s13045-020-00904-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing the rationale for targeting IGF axis in cancer. However, clinical trials of the type I IGF receptor (IGF-IR)-targeted agents have been largely disappointing. Accumulating evidence demonstrates that the IGF axis not only promotes tumorigenesis, but also confers resistance to standard treatments. Furthermore, there are diverse pathways leading to the resistance to IGF-IR-targeted therapy. Recent studies characterizing the complex IGFs signaling in cancer have raised hope to refine the strategies for targeting the IGF axis. This review highlights the biological activities of IGF-IR signaling in cancer and the contribution of IGF-IR to cytotoxic, endocrine, and molecular targeted therapies resistance. Moreover, we update the diverse mechanisms underlying resistance to IGF-IR-targeted agents and discuss the strategies for future development of the IGF axis-targeted agents.

引用

页数：17

共 211 条

[1] Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma [J].

Abdel-Wahab, Reham ;

Varadhachary, Gauri R. ;

Bhosale, Priya R. ;

Wang, Xuemei ;

Fogelman, David R. ;

Shroff, Rachna T. ;

Overman, Michael J. ;

Wolff, Robert A. ;

Javle, Milind .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11

[2] Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma [J].

Abraham, Jinu ;

Prajapati, Suresh I. ;

Nishijo, Koichi ;

Schaffer, Beverly S. ;

Taniguchi, Eri ;

Kilcoyne, Aoife ;

McCleish, Amanda T. ;

Nelon, Laura D. ;

Giles, Francis G. ;

Efstratiadis, Argiris ;

LeGallo, Robin D. ;

Nowak, Brent M. ;

Rubin, Brian P. ;

Malempati, Suman ;

Keller, Charles .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (04) :697-707

[3] Early neonatal death in mice homozygous for a null allele of the insulin receptor gene [J].

Accili, D ;

Drago, J ;

Lee, EJ ;

Johnson, MD ;

Cool, MH ;

Salvatore, P ;

Asico, LD ;

Jose, PA ;

Taylor, SI ;

Westphal, H .

NATURE GENETICS, 1996, 12 (01) :106-109

[4] Circulating insulin-like growth factor binding protein-3 and risk of gastrointestinal malignant tumors [J].

Adachi, Yasushi ;

Nojima, Masanori ;

Mori, Mitsuru ;

Kubo, Toshiyuki ;

Yamano, Hiro-o ;

Lin, Yingsong ;

Wakai, Kenji ;

Tamakoshi, Akiko .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (12) :2104-2111

[5] Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study [J].

Adachi, Yasushi ;

Nojima, Masanori ;

Mori, Mitsuru ;

Yamashita, Kentaro ;

Yamano, Hiro-o ;

Nakase, Hiroshi ;

Endo, Takao ;

Wakai, Kenji ;

Sakata, Kiyomi ;

Tamakoshi, Akiko .

WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (19) :3488-3495

[6] Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response [J].

Aiken, Robert ;

Axelson, Magnus ;

Harmenberg, Johan ;

Klockare, Maria ;

Larsson, Olle ;

Wassberg, Cecilia .

ONCOTARGET, 2017, 8 (46) :81501-81510

[7] Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage [J].

Aleksic, Tamara ;

Gray, Nicki ;

Wu, Xiaoning ;

Rieunier, Guillaume ;

Osher, Eliot ;

Mills, Jack ;

Verrill, Clare ;

Bryant, Richard J. ;

Han, Cheng ;

Hutchinson, Kathryn ;

Lambert, Adam G. ;

Kumar, Rajeev ;

Hamdy, Freddie C. ;

Weyer-Czernilofsky, Ulrike ;

Sanderson, Michael P. ;

Bogenrieder, Thomas ;

Taylor, Stephen ;

Macaulay, Valentine M. .

CANCER RESEARCH, 2018, 78 (13) :3497-3509

[8] IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer [J].

Aleksic, Tamara ;

Verrill, Clare ;

Bryant, Richard J. ;

Han, Cheng ;

Worrall, Andrew Ross ;

Brureau, Laurent ;

Larre, Stephane ;

Higgins, Geoff S. ;

Fazal, Fahad ;

Sabbagh, Ahmad ;

Haider, Syed ;

Buffa, Francesca M. ;

Cole, David ;

Macaulay, Valentine M. .

BRITISH JOURNAL OF CANCER, 2017, 117 (11) :1600-1606

[9] Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells [J].

Aleksic, Tamara ;

Chitnis, Meenali M. ;

Perestenko, Olga V. ;

Gao, Shan ;

Thomas, Peter H. ;

Turner, Gareth D. ;

Protheroe, Andrew S. ;

Howarth, Mark ;

Macaulay, Valentine M. .

CANCER RESEARCH, 2010, 70 (16) :6412-6419

[10] Dynamic and Nuclear Expression of PDGFRα and IGF-1R in Alveolar Rhabdomyosarcoma [J].

Aslam, M. Imran ;

Hettmer, Simone ;

Abraham, Jinu ;

LaTocha, Dorian ;

Soundararajan, Anuradha ;

Huang, Elaine T. ;

Goros, Martin W. ;

Michalek, Joel E. ;

Wang, Shuyu ;

Mansoor, Atiya ;

Druker, Brian J. ;

Wagers, Amy J. ;

Tyner, Jeffrey W. ;

Keller, Charles .

MOLECULAR CANCER RESEARCH, 2013, 11 (11) :1303-1313

← 1 2 3 4 5 6 7 8 9 10 →